Also known as: platinum-resistant epithelial ovarian
The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06545617 |
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer |
WITHDRAWN | PHASE1/PHASE2 |
| NCT05243524 |
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer |
TERMINATED | PHASE2 |
| NCT04244552 |
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies |
TERMINATED | PHASE1 |
| NCT03081702 |
A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer |
COMPLETED | PHASE1/PHASE2 |
